[Breaking] D&D Pharmatech's DD01 Shows Statistical Significance in Liver Biopsy Endpoints in U.S. Phase 2 MASH Trial... CSR Received
D&D Pharmatech announced in a regulatory filing on the 21st that it has received the Clinical Study Report (CSR) for its U.S. Phase 2 clinical trial of DD01, a treatment for metabolic dysfunction-associated steatohepatitis (MASH). The trial was conducted at 12 institutions in the United States to e
![[Breaking] D&D Pharmatech's DD01 Shows Statistical Significance in Liver Biopsy Endpoints in U.S. Phase 2 MASH Trial... CSR Received](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F07%2F587619%2Fdd061e922baccfcb%2Foriginal.webp&w=1920&q=75)
D&D Pharmatech announced in a regulatory filing on the 21st that it has received the Clinical Study Report (CSR) for its U.S. Phase 2 clinical trial of DD01, a treatment for metabolic dysfunction-associated steatohepatitis (MASH).
The trial was conducted at 12 institutions in the United States to evaluate the efficacy, safety, and tolerability of DD01 in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and MASH accompanied by overweight or obesity. A total of 67 participants were enrolled, receiving DD01 or a placebo as a once-weekly subcutaneous injection for 48 weeks.
The primary endpoint was the proportion of patients whose liver fat content, measured by MRI-PDFF at 12 weeks after dosing, decreased by at least 30% compared to baseline. The analysis showed this proportion was 75.8% in the DD01 group and 11.8% in the placebo group, a statistically significant difference between the two groups.
■ Significance Also Confirmed in Liver Biopsy Assessment
Statistically significant differences were also confirmed across the efficacy endpoints assessed through liver biopsies conducted after 48 weeks of treatment.
The proportion of patients with resolution of steatohepatitis without worsening of liver fibrosis was 62.5% in the DD01 group and 5.3% in the placebo group. The proportion of patients achieving both steatohepatitis resolution and liver fibrosis improvement was 37.5% in the DD01 group and 5.3% in the placebo group, also a statistically significant difference.
D&D Pharmatech stated that it plans to use the analysis of this clinical trial data as supporting material for future business development.
Meanwhile, the company noted in its investor cautionary statement that the probability of an investigational drug ultimately receiving approval as a medicine is known to be statistically around 10%, and that its commercialization plans may be changed or abandoned depending on the outcomes of the clinical and product approval processes.
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.
![[Breaking] Samsung Heavy Industries Wins 342.4 Billion Won Order for One LNG Carrier... 3.2% of Last Year's Revenue](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F06%2F579439%2F403aa2853abfc80b%2Fvariants%2Fhero.webp&w=1920&q=75)

![[Breaking] Dongwon Anatech (094170) Maintains 20,000-Won Level Even After Upside VI, Up 2.74%](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F06%2F585246%2Faa9a9903637bc86d%2Fvariants%2Fhero.webp&w=1920&q=75)
![[Breaking] EcoPro BM (247540) Falls Below VI Trigger Price-Exceeding 89,200 Won...Currently Slightly Up](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F06%2F585438%2Fce7a482a31ef35c4%2Fvariants%2Fhero.webp&w=1920&q=75)